Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy

Chong Zhao, Xin Chen, Dan Zang, Xiaoying Lan, Siyan Liao, Changshan Yang, Peiquan Zhang, Jinjie Wu, Xiaofen Li, Ningning Liu, Yuning Liao, Hongbiao Huang, Xianping Shi, Lili Jiang, Xiuhua Liu, Zhimin He, Xuejun Wang, Jinbao Liu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings of platinum-based chemotherapy but the inherent problem remains unsolved. Here we report that platinum pyrithione (PtPT), a chemically well-characterized synthetic complex of platinum, inhibits proteasome function and thereby exhibits greater and more selective cytotoxicity to multiple cancer cells than cisplatin, without showing discernible DNA damage both in vitro and in vivo. Moreover, unlike the classical proteasome inhibitor bortezomib/Velcade which inhibits the proteasome via blocking the peptidase activity of 20S proteasomes, PtPT primarily deactivates 26S proteasome-associated deubiquitinases USP14 and UCHL5. Furthermore, PtPT can selectively induce cytotoxicity and proteasome inhibition in cancer cells from leukemia patients but not peripheral blood mononuclear cells from healthy humans. In nude mice, PtPT also remarkably inhibited tumor xenograft growth, without showing the adverse effects that were induced by cisplatin. Hence, we have discovered a new platinum-based anti-tumor agent PtPT which targets 26S proteasome-associated deubiquitinases rather than DNA in the cell and thereby exerts safer and more potent anti-tumor effects, identifying a highly translatable new platinum-based anti-cancer strategy.

Original languageEnglish (US)
Pages (from-to)22-38
Number of pages17
JournalBiochemical Pharmacology
Volume116
DOIs
StatePublished - Sep 15 2016

Fingerprint

Platinum Compounds
Platinum
Cisplatin
Proteasome Endopeptidase Complex
Neoplasms
Therapeutics
Tumors
DNA
Cytotoxicity
DNA Damage
Cells
pyrithione
Proteasome Inhibitors
Chemotherapy
Drug Resistance
Heterografts
Nude Mice
Pharmaceutical Preparations
Toxicity
Blood Cells

Keywords

  • DNA damage
  • Deubiquitinases
  • Platinum pyrithione
  • Proteasome
  • Tumor

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. / Zhao, Chong; Chen, Xin; Zang, Dan; Lan, Xiaoying; Liao, Siyan; Yang, Changshan; Zhang, Peiquan; Wu, Jinjie; Li, Xiaofen; Liu, Ningning; Liao, Yuning; Huang, Hongbiao; Shi, Xianping; Jiang, Lili; Liu, Xiuhua; He, Zhimin; Wang, Xuejun; Liu, Jinbao.

In: Biochemical Pharmacology, Vol. 116, 15.09.2016, p. 22-38.

Research output: Contribution to journalArticle

Zhao, C, Chen, X, Zang, D, Lan, X, Liao, S, Yang, C, Zhang, P, Wu, J, Li, X, Liu, N, Liao, Y, Huang, H, Shi, X, Jiang, L, Liu, X, He, Z, Wang, X & Liu, J 2016, 'Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy', Biochemical Pharmacology, vol. 116, pp. 22-38. https://doi.org/10.1016/j.bcp.2016.06.019
Zhao, Chong ; Chen, Xin ; Zang, Dan ; Lan, Xiaoying ; Liao, Siyan ; Yang, Changshan ; Zhang, Peiquan ; Wu, Jinjie ; Li, Xiaofen ; Liu, Ningning ; Liao, Yuning ; Huang, Hongbiao ; Shi, Xianping ; Jiang, Lili ; Liu, Xiuhua ; He, Zhimin ; Wang, Xuejun ; Liu, Jinbao. / Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy. In: Biochemical Pharmacology. 2016 ; Vol. 116. pp. 22-38.
@article{49a6a7c3e05e47899c0a7c77d8059ef8,
title = "Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy",
abstract = "DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings of platinum-based chemotherapy but the inherent problem remains unsolved. Here we report that platinum pyrithione (PtPT), a chemically well-characterized synthetic complex of platinum, inhibits proteasome function and thereby exhibits greater and more selective cytotoxicity to multiple cancer cells than cisplatin, without showing discernible DNA damage both in vitro and in vivo. Moreover, unlike the classical proteasome inhibitor bortezomib/Velcade which inhibits the proteasome via blocking the peptidase activity of 20S proteasomes, PtPT primarily deactivates 26S proteasome-associated deubiquitinases USP14 and UCHL5. Furthermore, PtPT can selectively induce cytotoxicity and proteasome inhibition in cancer cells from leukemia patients but not peripheral blood mononuclear cells from healthy humans. In nude mice, PtPT also remarkably inhibited tumor xenograft growth, without showing the adverse effects that were induced by cisplatin. Hence, we have discovered a new platinum-based anti-tumor agent PtPT which targets 26S proteasome-associated deubiquitinases rather than DNA in the cell and thereby exerts safer and more potent anti-tumor effects, identifying a highly translatable new platinum-based anti-cancer strategy.",
keywords = "DNA damage, Deubiquitinases, Platinum pyrithione, Proteasome, Tumor",
author = "Chong Zhao and Xin Chen and Dan Zang and Xiaoying Lan and Siyan Liao and Changshan Yang and Peiquan Zhang and Jinjie Wu and Xiaofen Li and Ningning Liu and Yuning Liao and Hongbiao Huang and Xianping Shi and Lili Jiang and Xiuhua Liu and Zhimin He and Xuejun Wang and Jinbao Liu",
year = "2016",
month = "9",
day = "15",
doi = "10.1016/j.bcp.2016.06.019",
language = "English (US)",
volume = "116",
pages = "22--38",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy

AU - Zhao, Chong

AU - Chen, Xin

AU - Zang, Dan

AU - Lan, Xiaoying

AU - Liao, Siyan

AU - Yang, Changshan

AU - Zhang, Peiquan

AU - Wu, Jinjie

AU - Li, Xiaofen

AU - Liu, Ningning

AU - Liao, Yuning

AU - Huang, Hongbiao

AU - Shi, Xianping

AU - Jiang, Lili

AU - Liu, Xiuhua

AU - He, Zhimin

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2016/9/15

Y1 - 2016/9/15

N2 - DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings of platinum-based chemotherapy but the inherent problem remains unsolved. Here we report that platinum pyrithione (PtPT), a chemically well-characterized synthetic complex of platinum, inhibits proteasome function and thereby exhibits greater and more selective cytotoxicity to multiple cancer cells than cisplatin, without showing discernible DNA damage both in vitro and in vivo. Moreover, unlike the classical proteasome inhibitor bortezomib/Velcade which inhibits the proteasome via blocking the peptidase activity of 20S proteasomes, PtPT primarily deactivates 26S proteasome-associated deubiquitinases USP14 and UCHL5. Furthermore, PtPT can selectively induce cytotoxicity and proteasome inhibition in cancer cells from leukemia patients but not peripheral blood mononuclear cells from healthy humans. In nude mice, PtPT also remarkably inhibited tumor xenograft growth, without showing the adverse effects that were induced by cisplatin. Hence, we have discovered a new platinum-based anti-tumor agent PtPT which targets 26S proteasome-associated deubiquitinases rather than DNA in the cell and thereby exerts safer and more potent anti-tumor effects, identifying a highly translatable new platinum-based anti-cancer strategy.

AB - DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings of platinum-based chemotherapy but the inherent problem remains unsolved. Here we report that platinum pyrithione (PtPT), a chemically well-characterized synthetic complex of platinum, inhibits proteasome function and thereby exhibits greater and more selective cytotoxicity to multiple cancer cells than cisplatin, without showing discernible DNA damage both in vitro and in vivo. Moreover, unlike the classical proteasome inhibitor bortezomib/Velcade which inhibits the proteasome via blocking the peptidase activity of 20S proteasomes, PtPT primarily deactivates 26S proteasome-associated deubiquitinases USP14 and UCHL5. Furthermore, PtPT can selectively induce cytotoxicity and proteasome inhibition in cancer cells from leukemia patients but not peripheral blood mononuclear cells from healthy humans. In nude mice, PtPT also remarkably inhibited tumor xenograft growth, without showing the adverse effects that were induced by cisplatin. Hence, we have discovered a new platinum-based anti-tumor agent PtPT which targets 26S proteasome-associated deubiquitinases rather than DNA in the cell and thereby exerts safer and more potent anti-tumor effects, identifying a highly translatable new platinum-based anti-cancer strategy.

KW - DNA damage

KW - Deubiquitinases

KW - Platinum pyrithione

KW - Proteasome

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84983782464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983782464&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2016.06.019

DO - 10.1016/j.bcp.2016.06.019

M3 - Article

C2 - 27381943

AN - SCOPUS:84983782464

VL - 116

SP - 22

EP - 38

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -